Enhancing Malaria Vaccine Development by the Naval Medical Research Center
Abstract
A biopolymeric delivery system provided an effective new method for the introduction of plasmid DNA vaccines designed against malaria. During Milestone I of this Phase II project, the feasibility of this vaccine/polymer system was ascertained via characterization of plasmid impregnation and particle morphology. Particles of poly(D,L-lactide-co- glycolide) (PLGA) with incorporated DNA plasmid were developed for systemic administration of DNA plasmids for use as a malaria vaccine. Objectives in Milestone I included impregnation of intact plasmid DNA within a PLGA excipient and reduction in size of the pDNA/polymer matrix followed by monitoring release of the plasmid from the matrix. The outcomes of Milestone I studies demonstrated that the incorporated plasmid was intact, that the plasmid is incorporated within the matrix, and that polymer particle sizes were capable of being engulfed by antigen presenting cells. The plasmid/PLGA system demonstrated potential efficacy in vitro and development continued to produce a new vaccine system against malaria.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2003
- Accession Number
- ADA411924
Entities
People
- David D. Hile
- Debra J. Trantolo